Zhaozhen Wu
YOU?
Author Swipe
View article: Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study
Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study Open
View article: Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer
Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer Open
Dynamic CLR can serve as a potential biomarker for predicting the prognosis of SCLC patients treated with chemoimmunotherapy. Reduction of CLR after chemoimmunotherapy is associated with a significantly higher ORR and improved PFS.
View article: The efficacy and safety of chemotherapy with or without <scp>anti‐PD</scp>‐1 for the first‐line treatment of advanced urothelial carcinoma
The efficacy and safety of chemotherapy with or without <span>anti‐PD</span>‐1 for the first‐line treatment of advanced urothelial carcinoma Open
Objective To compare the efficacy and safety of first‐line anti‐PD‐1 combined with chemotherapy versus chemotherapy alone in patients with advanced urothelial carcinoma (UC). Method Patients with advanced UC who received first‐line treatme…
View article: Clinicopathological features and prognostic analysis of Her-2-negative breast mucinous adenocarcinoma: A SEER database analysis
Clinicopathological features and prognostic analysis of Her-2-negative breast mucinous adenocarcinoma: A SEER database analysis Open
Background Breast mucinous adenocarcinoma is a group of malignant tumors of epithelial origin of the breast with a good prognosis; however, whether its treatment regimen should be consistent with that of non-specific types of breast cancer…
View article: The gut microbiota modulates responses to anti–PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors
The gut microbiota modulates responses to anti–PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors Open
Background Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) have been widely used in treating different malignancies. Several studies have reported that the gut microbiota modulates the response and adve…
View article: Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis Open
Background Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have demonstrated promise in treating a variety of advanced cancers; however, little is known regarding their efficacy under various clinical situations, including di…
View article: Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting
Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting Open
Background Rationale exists for combining immune checkpoint inhibitors and PARP inhibitors (PARPi), and results of clinical trials in ovarian cancer are promising, but data in other cancers are limited. Method Efficacy and safety of PARPi/…
View article: The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors Open
Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated great promise for treating cancers with homologous recombination (HR) defects, such as germline BRCA1/2 mutation. Further studies suggest that PARP inhibitors (PARPi) can als…
View article: <p>Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors</p>
Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors Open
Pretreatment LIPI combined with a dNLR ≥ 3 and/or LDH ≥ ULN is associated with poor outcomes in patients with aHCC treated with PD-1 inhibitors. Further validation in large, prospective studies are warranted.
View article: Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma
Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma Open
View article: Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC Open
The efficacies of pembrolizumab and nivolumab have never been directly compared in a real-world study. Therefore, we sought to retrospectively evaluate the objective response rate (ORR) and the progression-free survival (PFS) of patients w…
View article: Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients
Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients Open
View article: Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer Open
Background: Cutaneous adverse events (AEs) have been positively associated with immune checkpoint inhibitor (ICI) efficacy in patients with melanoma, but little is known regarding the association between checkpoint inhibitor pneumonitis (C…
View article: Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer
Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer Open
View article: Downregulation of <scp>MCT</scp>4 for lactate exchange promotes the cytotoxicity of <scp>NK</scp> cells in breast carcinoma
Downregulation of <span>MCT</span>4 for lactate exchange promotes the cytotoxicity of <span>NK</span> cells in breast carcinoma Open
Monocarboxylate transporter‐4 ( MCT 4), a monocarboxylic acid transporter, demonstrates significantly increased expression in the majority of malignancies. We performed an experiment using BALB /C mice, and our results showed that Sh MCT 4…
View article: Methylglyoxal: A newly detected and potentially harmful metabolite in the blood of ketotic dairy cows
Methylglyoxal: A newly detected and potentially harmful metabolite in the blood of ketotic dairy cows Open
Ketosis causes serious economic losses for the modern dairy industry because it is a highly prevalent metabolic disease among cows in high-producing herds during the transition period. Due to some striking similarities between diabetes in …
View article: P2.01-045 The Efficiency of Apatinib plus S-1 as Laterline Chemotherapy for Advanced Non-Small-Cell Lung Cancer
P2.01-045 The Efficiency of Apatinib plus S-1 as Laterline Chemotherapy for Advanced Non-Small-Cell Lung Cancer Open
View article: PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism
PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism Open
PTEN has been studied in several tumor models as a tumor suppressor. In this study, we explored the role of PTEN in the inhibition state of polarized M2 subtype of macrophage in tumor microenvironment (TME) and the underlying mechanisms. T…